Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)

Conditions:   Breast Cancer;   Pancreas Cancer;   Prostate Cancer;   Lung Cancer;   Colon Cancer;   Esophagus Cancer;   Liver Cancer;   Ovary Cancer;   Lymphoma
Intervention:   Drug: NP-G2-044
Sponsors:   Novita Pharmaceuticals, Inc.;   Translational Drug Development
Not yet recruiting - verified June 2017

http://ift.tt/2tiPivK